Both SEPT2 and MLL are down-regulated in MLL-SEPT2 therapy-related myeloid neoplasia by Cerveira, Nuno et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Both SEPT2 and MLL are down-regulated in MLL-SEPT2 
therapy-related myeloid neoplasia
Nuno Cerveira1, Joana Santos1, Susana Bizarro1, Vera Costa1, 
Franclim R Ribeiro1, Susana Lisboa1, Cecília Correia1, Lurdes Torres1, 
Joana Vieira1, Simone Snijder2, José M Mariz3, Lucília Norton4, 
Clemens H Mellink2, Arjan Buijs5 and Manuel R Teixeira*1,6
Address: 1Department of Genetics, Portuguese Oncology Institute, Porto, Portugal, 2Department of Clinical Genetics, Academic Medical Center, 
Amsterdam, The Netherlands, 3Department of Hemato-Oncology, Portuguese Oncology Institute, Porto, Portugal, 4Department of Pediatrics, 
Portuguese Oncology Institute, Porto, Portugal, 5Department of Medical Genetics, University Medical Center, Utrecht, The Netherlands and 6Abel 
Salazar Biomedical Sciences Institute (ICBAS), Porto, Portugal
Email: Nuno Cerveira - nscerveira@gmail.com; Joana Santos - joana.cris.santos@gmail.com; Susana Bizarro - susanabizarro@gmail.com; 
Vera Costa - veralmcosta@gmail.com; Franclim R Ribeiro - ribeirofr@gmail.com; Susana Lisboa - susanalisboa@hotmail.com; 
Cecília Correia - correia.cecilia@gmail.com; Lurdes Torres - lurdes_torres@hotmail.com; Joana Vieira - joana_vieira@netcabo.pt; 
Simone Snijder - s.snijder@amc.uva.nl; José M Mariz - mariz@ipoporto.min-saude.pt; Lucília Norton - lucilia.norton@ipoporto.min-saude.pt; 
Clemens H Mellink - c.h.mellink@amc.uva.nl; Arjan Buijs - a.buijs@umcutrecht.nl; Manuel R Teixeira* - manuel.teixeira@ipoporto.min-
saude.pt
* Corresponding author    
Abstract
Background: A relevant role of septins in leukemogenesis has been uncovered by their involvement as fusion
partners in MLL-related leukemia. Recently, we have established the MLL-SEPT2 gene fusion as the molecular
abnormality subjacent to the translocation t(2;11)(q37;q23) in therapy-related acute myeloid leukemia. In this
work we quantified MLL and SEPT2 gene expression in 58 acute myeloid leukemia patients selected to represent
the major AML genetic subgroups, as well as in all three cases of MLL-SEPT2-associated myeloid neoplasms so far
described in the literature.
Methods: Cytogenetics, fluorescence in situ hybridization (FISH) and molecular studies (RT-PCR, qRT-PCR and
qMSP) were used to characterize 58 acute myeloid leukemia patients (AML) at diagnosis selected to represent
the major AML genetic subgroups: CBFB-MYH11 (n = 13), PML-RARA (n = 12); RUNX1-RUNX1T1 (n = 12), normal
karyotype (n = 11), and MLL gene fusions other than MLL-SEPT2 (n = 10). We also studied all three MLL-SEPT2
myeloid neoplasia cases reported in the literature, namely two AML patients and a t-MDS patient.
Results: When compared with normal controls, we found a 12.8-fold reduction of wild-type SEPT2 and MLL-
SEPT2 combined expression in cases with the MLL-SEPT2 gene fusion (p = 0.007), which is accompanied by a 12.4-
fold down-regulation of wild-type MLL and MLL-SEPT2 combined expression (p = 0.028). The down-regulation of
SEPT2 in MLL-SEPT2 myeloid neoplasias was statistically significant when compared with all other leukemia genetic
subgroups (including those with other MLL gene fusions). In addition, MLL expression was also down-regulated in
the group of MLL fusions other than MLL-SEPT2, when compared with the normal control group (p = 0.023)
Conclusion: We found a significant down-regulation of both SEPT2 and MLL in MLL-SEPT2 myeloid neoplasias.
In addition, we also found that MLL is under-expressed in AML patients with MLL fusions other than MLL-SEPT2.
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Background
Septins comprise an evolutionarily conserved family of
GTP-binding proteins that are found primarily in fungi
and animals [1]. In humans, 14 septin genes have been
characterized to date (SEPT1 to SEPT14). All septin tran-
scripts contain multiple translation initiation sites and are
alternatively spliced, giving origin to multiple septin iso-
forms, some of which are tissue specific [1]. Although the
precise functions of septins remain unclear, current data
suggest that they coordinate changes in cytoskeletal and
membrane organization by acting as scaffolds that recruit
factors to precise sites in a cell and/or as barriers that seg-
regate membrane areas into discrete domains [1,2]. For
instance, the human SEPT2 associates with SEPT6 and
SEPT7 to form an hexamer complex that is the core unit
for generation of septin filaments associated with the con-
tractile ring in dividing cells, being therefore essential for
proper cytokinesis and chromosome segregation [2,3].
Septins have been reported to be deregulated in various
human diseases, including cancer [4]. A relevant role of
septins in leukemogenesis has been uncovered by their
involvement as fusion partners in MLL-related leukemia.
We have established the MLL-SEPT2 gene fusion as the
molecular abnormality subjacent to the translocation
t(2;11)(q37;q23) in therapy-related acute myeloid leuke-
mia (t-AML) [5]. Subsequently, van Binsbergen et al [6]
identified a second MLL-SEPT2 fusion variant in a patient
with t-AML and we have recently uncovered a third MLL-
SEPT2  alternative fusion variant in a case of therapy-
related myelodysplastic syndrome (t-MDS) [7,8]. Four
other septin family genes (SEPT5,  SEPT6,  SEPT9  and
SEPT11) had previously been identified as MLL  fusion
partners in leukemia, making the septins the protein fam-
ily with more numbers involved in MLL-related leukemia
[9-13], and suggesting that their involvement in leukemo-
genesis is not a chance event. This hypothesis is supported
by the fact that all the reported MLL-septin fusions are in
frame and the breakpoints are found at the very 5' end of
known septin open reading frames [5,9-13]. In this work
we show evidence that the fusion of MLL with SEPT2 is
associated with down-regulation of both SEPT2 and MLL
expression in t-AML/t-MDS.
Methods
Patient samples
We studied 58 acute myeloid leukemia patients (AML) at
diagnosis selected to represent the major AML genetic sub-
groups, including 13 cases with a CBFB-MYH11 rearrange-
ment, 12 cases with a PML-RARA rearrangement, 12 cases
with a RUNX1-RUNX1T1 rearrangement, 11 cases with
normal karyotype, and 10 cases with rearrangements of
the MLL gene other than MLL-SEPT2 [see Additional file
1]. We also studied all three MLL-SEPT2 patients reported
in the literature, namely two with t-AML (patients 59 and
60) and the third with t-MDS (patient 61), which were the
primary targets of our investigation [see Additional file 1]
[5-8]. All but patients 60 and 61 were treated at the Portu-
guese Oncology Institute, Porto, Portugal, and bone mar-
row samples were obtained to perform cytogenetic and
molecular studies. Patients 60 and 61 were treated in the
Netherlands at the St. Antonius Hospital, Nieuwegein [6]
and the Amsterdam Academic Medical Center [7], respec-
tively, from whom cDNA was obtained.
As a control group we studied bone marrow samples
obtained from ten individuals studied for the purpose to
rule out a hematological disease.
This study was approved by the Portuguese Oncology
Institute ethic committee, and informed consent was
obtained from all patients.
Chromosome banding and molecular cytogenetics
The diagnostic bone marrow samples of the Portuguese
patients (cases 1 to 59) were cultured for 24 hours in
RPMI 1640 medium with GlutaMAX-I (Invitrogen, Lon-
don, UK) supplemented with 20% fetal bovine serum
(Invitrogen, London, UK). Chromosome preparations
were made by standard methods and banded by trypsin-
Leishman. Karyotypes were described according to the
International System for Human Cytogenetic Nomencla-
ture [14].
Whenever appropriate, fluorescence in situ hybridization
(FISH) analysis for specific fusion genes or rearrange-
ments was performed using dual-color, break-apart or
dual-fusion, probes (Vysis, Downers Grove, USA).
Chromosome banding and molecular cytogenetic analy-
ses of patients 60 and 61 were described previously [6,7].
RNA extraction and cDNA synthesis
Total RNA was extracted from the diagnostic bone mar-
row sample of patients 1 to 59 and controls using 1 ml of
Tripure isolation reagent (Roche Diagnostics, Indianapo-
lis, USA) and quantified in a NanoDrop ND-100 spectro-
photometer (NanoDrop Technologies, Wilmington,
USA). For cDNA synthesis, 1 μg of total RNA was sub-
jected to reverse transcription with random hexamers
using the Superscript III First-Strand Synthesis System for
RT-PCR (Invitrogen, Carlsbad, USA), according to the
manufacturer's instructions. The final cDNA was diluted
with 30 μl of H2O. cDNA quantity and quality were
assessed in a NanoDrop ND-100 spectrophotometer
(NanoDrop Technologies, Wilmington, USA).
Qualitative Reverse-Transcription Polymerase Chain 
Reaction (RT-PCR)
RT-PCR assays for detection of the fusion transcripts
RUNX1-RUNX1T1, CBFB-MYH11, and PML-RARA  were
performed on the diagnostic samples according to theBMC Cancer 2009, 9:147 http://www.biomedcentral.com/1471-2407/9/147
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BIOMED-1 protocol [15]. The primers and PCR reaction
conditions for the detection of rearrangements involving
the MLL gene were previously published [5,10,16-19].
Quantitative Real-Time Polymerase Chain Reaction (qRT-
PCR)
We have evaluated the mRNA expression of MLL  and
SEPT2  genes by qRT-PCR on an ABI PRISM 7000
Sequence Detection System (Applied Biosystems, Foster
City, USA). Primers and probes for MLL and SEPT2 were
derived from the published mRNA sequences of SEPT2
and MLL (GenBank accession nos. NM_001008491.1 and
NM_005933.2, respectively), and designed with Primer
Express 2.0 (Applied BioSystems) and purchased from
Metabion (Metabion, Martinsried, Deutschland) [see
Additional file 2]. Primers and probes for the ABL1 gene
(GenBank accession no. NM_005157), used as endog-
enous control, were previously described and approved
for qRT-PCR based diagnosis and minimal residual dis-
ease detection in leukaemic patients, due to be similarly
expressed in normal and diagnostic samples as well as
within normal samples [see Additional file 2] [20,21]. All
primers and probes were designed outside of MLL and
SEPT2 breakpoint cluster regions in exons 4–5 and exons
3–4, respectively. To determine the relative expression lev-
els of the target gene in each sample, the relative amount
of the target gene was calibrated to the relative amount of
the internal reference gene and expressed in terms of
ratios between the target and the reference that were then
multiplied by 100 for easier tabulation (target gene/ABL1
×100). PCR reactions were performed in a 25 μl volume
containing 5 μl of synthesized cDNA, 12.5 μl of TaqMan
universal PCR master mix, 0.3 μM of each primer and 0.2
μM of each probe. PCR was performed in separate wells
for each primer/probe set and each sample was run in trip-
licate. PCR parameters were as follows: 50°C for 2 min.,
95°C for 10 min., followed by 50 cycles at 95°C for 15 s.
and 60°C for 1 min. Each plate included non-template
controls and serial dilutions of a strongly expressing sam-
ple (MLL or SEPT2) to construct the standard curves.
Bisulfite treatment
Sodium bisulfite conversion of unmethylated (but not
methylated) cytosine residues to uracil in a sample of
genomic DNA obtained from MLL-SEPT2 case 59 (DNA
from MLL-SEPT2 cases 60 and 61 was not available) and
three normal controls was performed as previously
described [22]. Briefly, 500 ng of genomic DNA was dena-
tured with 0.3 M NaOH in a total volume of 21 μl for 20
min. at 50°C. A volume of 450 μl freshly prepared
bisulfite solution (2.5 M sodium bisulfite, 125 mM hyd-
roquinone, and 0.2 M NaOH) was added to each denatur-
ation reaction, and the mixture was incubated at 70°C for
3 hours in the dark. The resulting bisulfite-converted DNA
was then purified by using Wizard DNA purification resin
(Wizard DNA Clean-Up System; Promega, Madison, USA)
according to the manufacturer's instructions and eluted in
45 μl of water preheated at 70°C. The eluted DNA was
denatured in 0.3 M NaOH for 10 min. at room tempera-
ture. Finally, the bisulfite converted and denatured
genomic DNA was precipitated with 100% ethanol, dried,
resuspended in 30 μl of water, and stored at -20°C.
Quantitative Methylation-Specific Polymerase Chain 
Reaction (qMSP)
Due to the very low quantity of DNA available from MLL-
SEPT2 case 59, only the SEPT2 gene could be analyzed by
qMSP. The SEPT2 5'-CpG island was identified using the
CpG Island Searcher http://cpgislands.com[23] and the
SEPT2  genomic sequence (GenBank accession no.
NT_005416.12). That CpG island was found to encom-
pass the predicted SEPT2 promoter region using PROS-
CAN 1.7 [24]. Primers and probe for the SEPT2 5'-CpG
island were designed with Methyl Primer Express 1.0
(Applied BioSystems, Foster City, USA), and selected to
specifically amplify fully methylated bisulfite-converted
DNA [see Additional file 2]. Primers and probe for the
internal reference gene, ACTB  (GenBank accession no.
NM_001101), were described previously [25] and were
designed to amplify and detect a region of the gene that is
devoid of CpG nucleotides to normalize for DNA input in
each sample [see Additional file 2]. qMSP of the chemi-
cally modified DNA was performed in an ABI PRISM 7000
Sequence Detection System (Applied Biosystems, Foster
City, USA), as previously described [26]. In brief, fluores-
cence based real-time PCR assays were carried out in a
reaction volume of 20 μL, consisting of 16.6 mM ammo-
nium sulfate, 67 mM trizma preset, 6.7 mM MgCl2, 10
mM mercaptoethanol, 0.1% DMSO, 200 μM each of
dATP, dCTP, dGTP, and dTTP, 600 nM of each primer, 0.4
μL of Rox dye, 200 nM of probe, 1 unit of platinum Taq
polymerase (Invitrogen, Carlsbad, USA), and 2 μl of
bisulfite-modified DNA as a template. PCR was per-
formed in separate wells for each primer/probe set and
each sample was run in triplicate. PCR was performed
under the following conditions: 95°C for 2 min., fol-
lowed by 45 cycles of 95°C for 15 s. and 60°C for 1 min.
To ensure the specificity of the analysis, each 96-well PCR
plate had wells that contained completely methylated
DNA at all CpGs (positive control – CpGenome Universal
Methylated DNA, Chemicon Europe, Hampshire, UK), a
completely unmethylated DNA (negative control – CpG-
enome Universal Unmethylated DNA, Chemicon Europe,
Hampshire, UK), and multiple water blanks (contamina-
tion control). To determine the relative levels of methyl-
ated promoter DNA in each sample, we used serial
dilutions of the positive control DNA to construct the cal-
ibration curve. The values obtained (mean quantity) for
each target gene were divided by the respective values ofBMC Cancer 2009, 9:147 http://www.biomedcentral.com/1471-2407/9/147
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the internal reference gene (ACTB). The ratio thus gener-
ated, which constitutes an index of the percentage of input
copies of DNA that are fully methylated at the primer- and
probe-binding sites, was then multiplied by 100 for easier
tabulation (methylation level = target gene/reference gene
× 100).
Statistical analyses
Normalized expression values for MLL and SEPT2 were
compared among the different sample groups using the
non-parametric Kruskal-Wallis H and Mann-Whitney U
tests. The correlation between MLL and SEPT2 expression
values within each group was assessed using Pearson's
test. All analyses were performed using SPSS version 15.0
(SPSS, Chicago, USA).
Results
In all cases, RNA and/or cDNA quantity and quality was
evaluated and was found to be appropriate for expression
studies. The 260/280 and 260/230 absorbance ratios for
RNA samples were in the range of 1.8–2.2. For the cDNA
samples, the 260/280 and 260/230 sample absorbance
ratios were in the range of 1.6–2.0 and 1.8–2.2, respec-
tively.
Normalized expression levels for MLL and SEPT2 within
each sample group are depicted in Figure 1. Statistically
significant differences were observed for the combined
wild-type SEPT2 and MLL-SEPT2 expression in the MLL-
SEPT2 cases when compared with the normal controls,
showing a 12.8-fold lower median expression in the MLL-
SEPT2  subset (p = 0.007). Furthermore, the combined
wild-type SEPT2 and MLL-SEPT2 expression was signifi-
cantly lower (5.4 to 9.4 fold) in the MLL-SEPT2 cases than
in all other leukemia genetic subgroups (Table 1). The
combined expression of wild-type MLL and MLL-SEPT2
was also significantly lower (12.4 fold; p = 0.028) in the
MLL-SEPT2 myeloid neoplasias when compared with the
normal controls, as well as with the CBFB-MYH11 and
RUNX1-RUNX1T1  leukemia subgroups (13.4 and 10.5
fold, respectively). We next investigated whether DNA
hypermethylation of the 5' SEPT2 region was contributing
to the SEPT2  gene down-regulation, by examining the
methylation status of the CpG island located upstream of
the SEPT2 gene transcriptional initiation site [2225 base
pair (bp) in length (-7457 to -9257)]. SEPT2  5' CpG
island hypermethylation was detected in the positive con-
trol, but not in the MLL-SEPT2 case 59 or the normal con-
trols.
No statistically significant differences were observed for
the wild-type SEPT2  expression between the non-MLL-
SEPT2 leukemia subgroups and the normal controls, with
the exception of the PML-RARA and "normal karyotype"
leukemias that showed lower expression (Table 1). No
statistically significant differences were observed for the
wild-type MLL expression between the non-MLL-SEPT2
leukemia subgroups and the normal controls, with the
exception of the significantly lower expression seen in the
patient group with MLL fusions with other partners other
than SEPT2 (q = 0,023).
Discussion
Fusion oncogenes are generally thought to contribute to
carcinogenesis by either causing over-expression of the 3'
partner due to promoter swap or by originating a chimeric
Box-plots of normalized expression values for SEPT2 (A) and  MLL (B) in subgroups of myeloid malignancies and control  samples Figure 1
Box-plots of normalized expression values for SEPT2 
(A) and MLL (B) in subgroups of myeloid malignan-
cies and control samples. Asterisks denote significant dif-
ferences when compared with the normal control group. 
The combined expression of MLL-SEPT2 and MLL or SEPT2 
was significantly lower in MLL-SEPT2 patients compared to all 
other groups (see Table 1 for significance values).BMC Cancer 2009, 9:147 http://www.biomedcentral.com/1471-2407/9/147
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protein with new biochemical properties. Surprisingly,
when compared with the normal controls, we found a
12.8-fold reduction of the combined MLL-SEPT2  and
wild-type SEPT2 expression in myeloid neoplasias with
the MLL-SEPT2  gene fusion, which is accompanied by
12.4-fold down-regulation of the combined MLL-SEPT2
and wild-type MLL expression. The down-regulation of
SEPT2 in MLL-SEPT2 myeloid neoplasias was also statisti-
cally significant when compared with all other leukemia
genetic subgroups (including those with other MLL gene
fusions). It is conceivable that deregulation of SEPT2
expression can occur as a result of its fusion with MLL (for
example by haplo-insufficiency), since the MLL-SEPT2
gene is under the control of the MLL promoter. However,
not only the magnitude of SEPT2 under-expression far
exceeds the maximum 50% reduction that would be
expected if one of the SEPT2 gene copies has its expression
shutdown, but wild-type MLL  expression seems to be
strongly down-regulated as well. This suggests a concomi-
tant down-regulation of wild-type MLL, wild-type SEPT2,
and the MLL-SEPT2  fusion gene. The fact that MLL,
SEPT2, and MLL-SEPT2  map to distinct chromosomes
excludes a localized transcriptional repression affecting
contiguous genes via a long-range control element as a
possible mechanism.
Interestingly, MLL expression was also down-regulated in
the group of MLL fusions other than MLL-SEPT2, when
compared with the normal control group. Wild-type MLL
down-regulation associated with MLL abnormalities was
previously observed in AML with MLL  partial tandem
duplication (PTD) [27]. In that instance, the wild-type
MLL  transcript derived from the non-rearranged MLL
allele was absent in the majority of cases of MLL-PTD,
with the authors suggesting that the silencing of wild-type
MLL may result from the action of the MLL-PTD protein
via an auto-regulatory mechanism [27], which has so far
not been described for MLL-SEPT2. In addition, down-
regulation of MLL when fused with a partner gene was
also previously observed in MLL-MLLT3  patients [27],
suggesting that this can be a common event in MLL-
related leukemia. Since MLL fusion proteins seem to
transform by a gain-of-function mechanism with conver-
sion of the MLL chimera into a potent transcriptional acti-
vator [28,29], quantitative oscillations in wild-type and
chimeric MLL expression level presumably do not abro-
gate the leukemogenic properties of MLL fusion proteins.
One alternative explanation for the observed down-regu-
lation of MLL, SEPT2 and MLL-SEPT2 is the involvement
of a transcriptional rather than post-transcriptional mech-
anism, for instance regulated via an epigenetic mark. DNA
methylation within the promoter region of a gene can
result in chromatin compaction and inhibition or down-
regulation of gene transcription, and aberrant promoter
methylation in cis is often responsible for gene silencing
in a variety of malignancies [30]. However, the absence of
DNA methylation in the CpG island located 5' of the
SEPT2 gene (encompassing the predicted SEPT2 promoter
region) suggests that hypermethylation of wild-type
SEPT2 is probably not the mechanism responsible for the
observed gene silencing but, since in only one MLL-SEPT2
case DNA was available to perform methylation analysis,
a definitive conclusion cannot be draw.
Table 1: Normalized values for the expression of MLL-SEPT2 and MLL or SEPT2 in subgroups of hematologic malignacies and normal 
controls
SEPT2 + MLL-SEPT2 MLL + MLL-SEPT2
Genetic groups n Median
(P25–P75)
Fold Change (a) P-value (a) P-value (b) Median
(P25–P75)
Fold Change (a) P-value (a) P-value (b)
CBFB-MYH11 13 3388
(2411–5634)
9.4 0.004 Ns 2692
(1698–5099)
13.4 0.025 ns
PML-RARA 12 1957
(1055–2904)
5.4 0.004 0.001 1083
(971–2698)
5.4 ns ns
RUNX1-RUNX1T1 12 3187
(2100–3760)
8.9 0.004 ns 2107
(1765–3018)
10.5 0.018 ns
Normal Karyotype 11 2242
(1604–3424)
6.2 0.005 0.010 1621
(1012–2895)
8.1 ns ns
MLL Fusions 10 3069
(2159–4600)
8.5 0.007 ns 1292
(708–2050)
6.4 ns 0.023
MLL-SEPT2 33 5 9
(333–724)
1.0 -0 . 0 0 7200
(180–1612)
1.0 -0 . 0 2 8
Normal Control 10 4599
(2939–6365)
12.8 0.007 - 2494
(1749–3929)
12.4 0.028 -
(a) Comparison of each group with MLL-SEPT2 patients; (b) Comparison of each group with normal control group; (P25) percentile 25; (P75) 
percentile 75.BMC Cancer 2009, 9:147 http://www.biomedcentral.com/1471-2407/9/147
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How can SEPT2  down-regulation be associated with
leukemogenesis? Mammalian septins have been linked
with two distinct steps in cell division, namely during
chromosome segregation and during cytokinesis, as
depletion of septins by siRNA result in defects in both of
these processes [31,32]. SEPT2 function is dependent of
the formation of core oligomeric complexes with SEPT6
and SEPT7, and this septin heterotrimer is a recognized
regulator of microtubule stability, with septin depletion
resulting in a marked stabilization of microtubules and
mitotic defects in vivo [1,33]. It is known that proper
organization of the cytoskeleton, including that of septin
filaments, is required for cell-cycle progression and, as a
consequence, septins are indirectly involved in driving or
halting the cell-cycle engine [34]. In addition, the SEPT2-
SEPT6-SEPT7 complex can directly regulate cell-cycle pro-
gression by sequestering key signaling molecules involved
in the DNA damage response and cell-cycle progression
[33,34]. Down-regulation of the expression of septin
genes has been described previously in neoplasia. Expres-
sion of the mitochondrial ARTS protein, a splice variant of
the SEPT4 gene, is lost in the majority of childhood acute
lymphoblastic leukemias and SEPT9 expression is down-
regulated by promoter methylation in head and neck
squamous cell carcinomas, suggesting that both genes can
function as tumor suppressor genes [35,36]. SEPT2 may
also play a role in the pathogenesis of other AML subtypes
in which it is not involved as fusion partner, since we have
uncovered significant SEPT2  RNA down-regulation in
AML associated with the PML-RARA rearrangement and in
AML with a normal karyotype.
SEPT2 is not the only septin family gene associated with
hematological neoplasia. It has been shown that at least
four other septins, SEPT5, SEPT6, SEPT9 and SEPT11, are
also MLL fusion partners [9-13]. There is increasing evi-
dence supporting the hypothesis that MLL fusion partners
are not randomly chosen, but rather functionally selected.
For instance, the most frequent MLL fusion partners AFF1
(AF4), MLLT3 (AF9), MLLT1 (ENL) and MLLT10 (AF10)
have been shown to belong to the same nuclear protein
network [37]. Furthermore, the carboxyl-terminal domain
of ELL and MLLT10 have been shown to be required for
the leukemic transformation associated with the MLL-ELL
and MLL-MLLT10 fusion proteins, respectively [38,39].
Conclusion
We provide evidence of MLL and SEPT2 down-regulation
in MLL-SEPT2 myeloid neoplasia, as well as MLL under-
expression in AML with MLL fusions with other partners
other than SEPT2 but, due to the small number of MLL-
SEPT2 cases available, these results should be confirmed
in a larger series of patients. Characterization of the
expression profile of other MLL fusion partners, including
other septins, in hematological malignancies may allow a
better understanding of the pathobiological mechanisms
of AML.
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